Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 7Breast Neoplasms 7Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Recurrence 3Pancreatic Neoplasms 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Congenital Abnormalities 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2

Interventions

mirdametinib 2tipifarnib 1pirfenidone 1emvododstat 1cabozantinib 1binimetinib 1Sunitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibromatoses × tipifarnib × Clear all
NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
62 enrolled 13 charts
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡